# US 8,278,310 B2 · Amine salts of a CRTH2 antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,310 B2
- Document ID: US8278310B2
- Status: Granted
- Kind: B2
- Application number: 12/665,705
- Filed: 2008-06-18
- Published: 2011-02-10
- Granted: 2012-10-02
- Earliest claimed: 2007-06-21
- Assignees: Actimis Pharmaceuticals, Inc.
- Inventors: Tai Wei Ly
- Web page: https://patentgrep.com/patent/US8278310B2

## CPC

- C07D 239/48: Two nitrogen atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are amine salts of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}-acetic acid, processes for their preparation, pharmaceutical compositions containing them, and their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.

## Claims

### Claim 1

A salt in a crystalline form, comprising ethylenediamine and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid of Formula I:
wherein the crystalline form has an X-ray powder diffraction pattern with a peak expressed in two-theta at approximately 5.9°, 11.6°, 17.5° and 29.4°.

### Claim 2 (depends on 1)

The salt of claim 1, comprising of about two molar equivalents of the acid of Formula I and about one molar equivalent of ethylenediamine.

### Claim 3 (depends on 1)

The salt of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 2.

### Claim 4 (depends on 1)

The salt of claim 1, having a differential scanning calorimetric thermogram substantially as shown in FIG. 3.

### Claim 5 (depends on 1)

The salt of claim 1, having a DSC thermogram with an endotherm at a peak temperature of about 123° C. and an onset temperature of about 114° C.

### Claim 6 (depends on 1)

The salt of claim 1, having a DSC thermogram with an endotherm at a peak temperature of about 216° C. and an onset temperature of about 212° C.

### Claim 7 (depends on 1)

The salt of claim 1, having an aqueous solubility of about 6 mg/mL at 25° C.

### Claim 8

A salt in a crystalline form, comprising piperazine and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid of Formula I:
wherein the crystalline form has an X-ray powder diffraction pattern with a peak expressed in two-theta at approximately 10.7, 15.9, 22.3, or 24.0°.

### Claim 9 (depends on 8)

The salt of claim 8, comprising of about two molar equivalents of the acid of Formula I and about one molar equivalent of piperazine.

### Claim 10 (depends on 8)

The salt of claim 8, having an X-ray powder diffraction pattern substantially as shown in FIG. 7.

### Claim 11 (depends on 8)

The salt of claim 8, having a differential scanning calorimetric thermogram substantially as shown in FIG. 8.

### Claim 12 (depends on 8)

The salt of claim 8, having a DSC thermogram with an endotherm at a peak temperature of about 203° C. and an onset temperature of about 198° C.

### Claim 13 (depends on 8)

The salt of claim 8, having a DSC thermogram with an endotherm at a peak temperature of about 223° C. and an onset temperature of about 219° C.

### Claim 14 (depends on 8)

The salt of claim 8, having an aqueous solubility of about 5 mg/mL at 25° C.

### Claim 15

A salt in a crystalline form, comprising benzathine and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid of Formula I:
wherein the crystalline form has an X-ray powder diffraction pattern with a peak expressed in two-theta at approximately 8.0, 11.5, 16.0, 17.5, or 23.4°.

### Claim 16 (depends on 15)

The salt of claim 15, comprising of about two molar equivalents of the acid of Formula I and about one molar equivalent of benzathine.

### Claim 17 (depends on 15)

The salt of claim 15, having an X-ray powder diffraction pattern substantially as shown in FIG. 12.

### Claim 18 (depends on 15)

The salt of claim 15, having a differential scanning calorimetric thermogram substantially as shown in FIG. 13.

### Claim 19 (depends on 15)

The salt of claim 15, having a DSC thermogram with an endotherm at a peak temperature of about 156° C. and an onset temperature of about 154° C.

### Claim 20 (depends on 15)

The salt of claim 15, having an aqueous solubility of about 0.08 mg/mL at 25° C.

### Claim 21

A salt in a crystalline form, comprising choline and {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid of Formula I:
wherein the crystalline form has an X-ray powder diffraction pattern with a peak expressed in two-theta at approximately 6.5, 19.6, 20.0, 21.9, or 26.1°.

### Claim 22 (depends on 21)

The salt of claim 21, comprising of about one molar equivalent of the acid of Formula I and about one molar equivalent of choline.

### Claim 23 (depends on 21)

The salt of claim 21, having an X-ray powder diffraction pattern substantially as shown in FIG. 16.

### Claim 24 (depends on 21)

The salt of claim 21, having a differential scanning calorimetric thermogram substantially as shown in FIG. 17.

### Claim 25 (depends on 21)

The salt of claim 21, having a DSC thermogram with an endotherm at a peak temperature of about 195° C. and an onset temperature of about 193° C.

### Claim 26 (depends on 21)

The salt of claim 21, having an aqueous solubility of about 24 mg/mL at 25° C.

### Claim 27 (depends on 1)

A pharmaceutical composition comprising the salt of claim 1, and a pharmaceutically acceptable carrier or excipient.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the composition is formulated for oral, nasal, bronchial, or topical administration.

### Claim 29 (depends on 27)

The pharmaceutical composition of claim 27, wherein the composition is formulated as a single dosage form.

### Claim 30 (depends on 1)

A process for the preparation of the salt of claim 1, comprising reacting {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)-pyrimidin-5-yl}acetic acid with the amine in a solvent at a first predetermined temperature.

### Claim 31 (depends on 30)

The process of claim 30, further comprising precipitating the salt at a second predetermined temperature.

### Claim 32 (depends on 1)

A process for the preparation of the salt of claim 1, comprising the steps of:
(a) generating the amine salt by reacting {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}acetic acid with the amine in a solvent at a first predetermined temperature; and
(b) precipitating the amine salt at a second predetermined temperature.

### Claim 33 (depends on 30)

The process of claim 30, wherein the first temperature is from about −10 to about 150° C.

### Claim 34 (depends on 30)

The process of claim 30, wherein the first temperature is from about 20 to 100° C.

### Claim 35 (depends on 31)

The process of claim 31, wherein the second temperature is from about −50 to 50° C.

### Claim 36 (depends on 31)

The process of claim 31, wherein the second temperature is from about −23 to 35° C.

### Claim 37 (depends on 30)

The process of claim 30, wherein the solvent is selected from the group consisting of methanol, ethanol, isopropanol, propanol, tetrahydrofuran, water, and mixtures thereof.

### Claim 38 (depends on 30)

The process of claim 30, wherein an anti-solvent is added in the precipitating step to effect precipitation.

### Claim 39 (depends on 38)

The process of claim 38, wherein the anti-solvent is selected from the group consisting of water, alkanes, ethers, aromatic hydrocarbons, and mixtures thereof.
